Navigation Links
Chemicals today, drugs tomorrow: U-M's new Center for Drug Discovery
Date:8/29/2012

ANN ARBOR, Mich.-- A new center at the University of Michigan will accelerate the progression to the marketplace of drugs under development at laboratories across campus.

Called the Center for the Discovery of New Medicines (CDNM), it will coordinate and support work in a range of departments and schools to streamline drug discovery and development, support the translation of early research toward patient usea gray area where funding is scarceand fully leverage the technical capabilities and intellectual resources at U-M in service of discovering the therapies of tomorrow.

"The CDNM will be a central hub for a dynamic community of researchers working on cures for devastating diseases," said Phil Hanlon, U-M povost and executive vice president for academic affairs. "Making collaborations possible and offering expert guidance throughout the process will catalyze activity in this area."

Funding for early stage drug discoveryidentifying pathways involved in disease and finding ways to interact with those pathwayshas declined in the pharmaceutical industry. The National Institutes of Health has recently increased funding for translational research, but the investment is insufficient and many projects frequently languish without the financial support to conduct the next stage of development.

The CDNM is a virtual organization founded by multiple schools and departments at U-M that are involved in biomedical research. Through rapid-access seed grants and twice-yearly pilot grant competitions, the CDNM will fund crucial steps in the drug discovery process while linking facilities that are currently unconnected.

"There is a lot of exciting work happening in drug discovery at U-M, but it's fragmented," said Rick Neubig, professor of pharmacology and director of the CDNM. "By marrying the power of chemical diversity with the broad reach and expertise of Michigan biologists, we expect a big impact."

Disease areas in which U-M is making the most immediate progress are cancer, inflammation, orphan and metabolic diseases and neurodegeneration, Neubig said.

The participating organizations at U-M pooled about $500,000 a year for the next three years to distribute as grants. Neubig expects the CDNM will fund 10 to 15 projects a year. Tenure-track and research-track faculty members at U-M will be able to apply. Applications for the first round of grants are due Oct. 1.

"The NIH is increasingly awarding its research funding to translational areas like innovative pharmacology and drug discovery," said Dr. James O. Woolliscroft, dean of the U-M Medical School. "The center will help position us to compete for this funding." The CDNM will also be a hub to connect U-M researchers with commercial partners and foundations, Neubig said, adding that he expected the CDNM to help stimulate the region's economy.

"The CDNM can really maximize the potential for academic drug discovery at U-M and accelerate the discovery of new therapeutics," said David Sherman, the Hans W. Vahlteich Professor of Medicinal Chemistry and associate dean for research and graduate education in U-M's College of Pharmacy and a Life Sciences Institute faculty member. "We hope this work will lead to increased business development around drug discovery, which has the potential ripple throughout the industry and the region."

The CDNM is distinguished from academic drug discovery efforts at other institutions by the breadth and depth of U-M's biomedical research, its capabilities in areas like medicinal chemistry and pharmacokinetics that are traditionally associated with the pharmaceutical industry, unique natural product extract libraries and a data-sharing system that increases efficiency and supports collaboration.

"Universities play a critical and growing role in early-stage drug discovery," said Dr. Jeff Leiden, chairman, CEO and president of Vertex Pharmaceuticals. "The work of academic researchers who are identifying and testing promising new targets and compounds is an important step in developing new breakthrough drugs for serious diseases. Collaborations between academic groups and biotech companies are increasingly important in discovering the next generation of transformational medicines."

U-M has the technological infrastructure critical to early stage drug development, but because the scientists working in this area are spread throughout the university, collaboration is sometimes difficult.

"We've seen firsthand the progress than can be made when scientists are able to work together spontaneously and smoothly," said Alan Saltiel, the Mary Sue Coleman Director of the Life Sciences Institute. "The CDNM will make it possible for scientists with promising discoveries to work together in new and highly productive ways to further develop potential treatments."


'/>"/>

Contact: Laura J. Williams
lauralw@umich.edu
734-615-4862
University of Michigan
Source:Eurekalert

Related biology news :

1. Effect of chronic exposure to chemicals used as weapons, pesticides under study
2. Production of chemicals without petroleum
3. Hormone-mimicking chemicals cause inter-species mating
4. Hearing the telltale sounds of dangerous chemicals
5. Newly released FDA draft guidelines for biosimilar drugs to be discussed at conference
6. Nanopills release drugs directly from the inside of cells
7. Genetic variation in East Asians found to explain resistance to cancer drugs
8. Discovery provides blueprint for new drugs that can inhibit hepatitis C virus
9. Internet and new drugs: A challenge for public health
10. Study raises questions about use of anti-epilepsy drugs in newborns
11. Drugs from lizard saliva reduces the cravings for food
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... , Jan. 12, 2017  New research undertaken by ... office of the future.  1,000 participants were simply asked which ... months which we may consider standard issue.  Insights on what ... 2017 were also gathered from futurists and industry leaders including ... James Canton .  Some of ...
(Date:1/6/2017)... Colo. , Jan. 5, 2017  SomaLogic ... the "Digital Life Alliance" established by iCarbonX, the ... 2015 to build a "Global Digital Health Ecosystem ... on a combination of individual,s biological, behavioral and ... the agreement between the companies, SomaLogic will provide ...
(Date:12/22/2016)... -- As part of its longstanding mission to improve genetic literacy ... released its latest children,s book, titled The One ... topics of inheritance and variation of traits that are part ... school classrooms in the US. The book ... Killoran , whose previous book with 23andMe, You ...
Breaking Biology News(10 mins):
(Date:1/12/2017)... 12, 2017 A new report published by Allied Market Research ... Opportunity Analysis and Industry Forecast, 2014-2022," projects that the global in vitro toxicity testing ... a CAGR of 15.07% during the forecast period. Continue ... ... ...
(Date:1/11/2017)... ... January 11, 2017 , ... Phase 1 clinical ... promise of the investigational anti-cancer agent tucatinib (formerly ONT-380) against HER2+ breast cancer. ... Twenty-seven percent of these heavily pretreated patients saw clinical benefit from the drug, ...
(Date:1/11/2017)... ... January 11, 2017 , ... ... for optics and photonics , are commending the U.S. Congress and President Obama ... Friday by the President of the American Innovation and Competitiveness Act (AICA). , ...
(Date:1/11/2017)... ... January 11, 2017 , ... While the most ... it is becoming increasingly clear that the evolution and transmission dynamics of resistance ... in the study of clinical resistance, has vastly underestimated these reservoirs of resistance ...
Breaking Biology Technology: